Legend Biotech names interim CEO after Ying Huang steps down

Legend Biotech Corporation (NASDAQ: LEGN) announced that Ying Huang, Ph.D., has stepped down as Chief Executive Officer and as a member of the Board of Directors, effective July 24, 2026. Dr. Huang will remain as an advisor through August to support the transition.

The Board has appointed Alan Bash, current President of the CARVYKTI Business Unit, as Interim Chief Executive Officer. The Board has also initiated a search process to identify a permanent successor.

Frank Zhang, Chairman of the Board, attributed Dr. Huang's seven-year tenure with advancing the company's commercial and clinical operations. "During his tenure, Legend Biotech advanced from a pioneering cell therapy company into a global leader with a strong commercial foundation, a differentiated innovation platform, and a clear commitment to patients," Zhang said.

Bash said his immediate focus will be on continuity across the business. "My immediate focus will be on ensuring continuity across the business, maintaining strong execution, and supporting our teams as we continue advancing our commercial, clinical, and operational priorities," he said.

Legend Biotech, headquartered in Bridgewater, N.J., develops and markets CARVYKTI, a CAR-T cell therapy for relapsed or refractory multiple myeloma, in collaboration with Johnson & Johnson.

You May Also Be Interested In

• Spero Therapeutics names new chief medical officer
• Profusa signs term sheet to acquire diagnostics firm with $111M revenue
• Entera Bio prices $275M private placement led by BVF Partners